Sensei Biotherapeutics (NASDAQ:FTH) Shares Climb 5.6% - Time to Buy?

Key Points

• Sensei Biotherapeutics shares rose 5.6% to about $29.63, though trading volume was 68% below the average session volume.
• Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and an average price target of $56.25, despite some sell ratings.
• The clinical-stage biotech beat quarterly EPS estimates, reporting a loss of $2.84 per share versus the expected $5.04 loss; analysts still project a full-year loss of $13.69 per share.

Sensei Biotherapeutics, Inc. (NASDAQ:FTH - Get Free Report)'s share price shot up 5.6% during trading on Wednesday. The company traded as high as $28.93 and last traded at $29.6290. 75,545 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 237,252 shares. The stock had previously closed at $28.07.

Analysts Set New Price Targets

FTH has been the subject of a number of research reports. Needham & Company LLC assumed coverage on Sensei Biotherapeutics in a report on Friday, August 21st. They set a "buy" rating and a $56.00 price objective for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Sensei Biotherapeutics in a research note on Monday, September 14th. Wall Street Zen downgraded Sensei Biotherapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. JonesTrading began coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, August 4th. They set a "buy" rating and a $55.00 price target for the company. Finally, Raymond James Financial began coverage on shares of Sensei Biotherapeutics in a report on Friday, July 31st. They issued an "outperform" rating and a $56.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $56.25.

Sensei Biotherapeutics Trading Up 6.1%

The firm's fifty day moving average price is $32.05. The company has a market cap of $769.77 million, a P/E ratio of -0.21 and a beta of -0.28.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.04) by $2.20. As a group, sell-side analysts anticipate that Sensei Biotherapeutics, Inc. will post -13.69 EPS for the current fiscal year.

Institutional Investors Weigh In On Sensei Biotherapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC acquired a new position in Sensei Biotherapeutics during the second quarter worth $307,000. Renaissance Technologies LLC lifted its stake in Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company's stock valued at $1,010,000 after acquiring an additional 20,525 shares during the last quarter. Bank of America Corp DE lifted its stake in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock valued at $1,041,000 after acquiring an additional 32,719 shares during the last quarter. Stempoint Capital LP bought a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at about $4,188,000. Finally, Alyeska Investment Group L.P. bought a new position in shares of Sensei Biotherapeutics in the 2nd quarter valued at about $3,610,000. Institutional investors own 10.50% of the company's stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company's research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei's technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.